Title : Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.

Pub. Date : 2019 Jul 15

PMID : 30940655






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Moreover, RET and Src co-high expression was an independent unfavorable prognosis factor in melanoma patients with or without ICB through inhibiting the antitumor immune response. indole-2-carboxylic acid SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens
2 CONCLUSIONS: Our data unveiled a new mechanism of alleviating IFNgamma-induced PD-L1 and IDO1 expression and provided a rationale to explore a novel combination of ICB with regorafenib clinically, especially in melanoma with RET/Src axis activation. indole-2-carboxylic acid SRC proto-oncogene, non-receptor tyrosine kinase Homo sapiens